NYSE To Suspend Trading Immediately In Lannett Co And Commence Delisting Proceedings

4/20/23 6:54:48 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LCI alert in real time by email

Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15,000,000 over a consecutive 30-trading day period.

Get the next $LCI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LCI

Date	Price Target	Rating	Analyst
8/31/2021	$7.00 → $6.00	Neutral	Roth Capital

More analyst ratings

$LCI
Press Releases

Fastest customizable press release news feed in the world

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo
4/20/23 6:53:00 AM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care
LANNETT SHARES UPDATE
Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure to Pay Interest on Convertible Notes TREVOSE, Pa., April 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.
4/4/23 6:55:00 AM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin
2/1/23 4:15:00 PM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo
4/20/23 6:53:00 AM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin
2/1/23 4:15:00 PM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a
1/25/23 6:52:00 AM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care

Why This Lucid Analyst Is Bullish On The EV Maker Despite Q3 Disappointment
Premium electric vehicle manufacturer Lucid Group, Inc. (NASDAQ:LCI) reported below-consensus third-quarter revenue and also lowered its production guidance for 2023. The stock has reacted to the results with a move to the downside. Notwithstanding the subpar results, Needham analyst Chris Pierce reiterated a Buy rating on the stock. He lowered his price target from $9 to $5. Needham’s Bullish Thesis: Pierce premised his optimism regarding Lucid on the company’s “industry-leading” battery and drive-train technology. “We continue… to see legacy OEMs struggle to make affordable EVs, with LCID a willing potential technology partner to drive down costs, particularly on the battery tech side,”
11/8/23 8:17:21 AM ET
$LCID
$LCI
Auto Manufacturing
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Tesla Soars 10% Amid Musk's China Visit, Lucid Slumps On Stock Sale, Ford-Uber's Win-Win Partnership And More: Biggest EV Stories Of The Week
Electric vehicle stocks closed the week ending May 19 on a mixed note, with market leader Tesla, Inc. (NASDAQ:TSLA) having a strong run amid CEO Elon Musk's first China visit since the COVID-19 pandemic. Here are the key events that happened in the EV space during the week: Musk Reserves High Praise For China Team, Model 3 Gets Tax Incentives: Musk's China visit took center stage this week as the billionaire visited Tesla's Giga Shanghai plant and met with Chinese government officials, including Foreign Minister Qin Gang and Minister of Industry and Information Technology Jin Zhuanglong. He also held discussions with Shanghai Party Secretary Chen Jining and had an audience with China's
6/3/23 9:14:15 AM ET
$F
$LI
$NIO
$RIVN
Auto Manufacturing
Consumer Discretionary
Business Services
Biotechnology: Pharmaceutical Preparations
NYSE To Suspend Trading Immediately In Lannett Co And Commence Delisting Proceedings
Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15,000,000 over a consecutive 30-trading day period.
4/20/23 6:54:48 AM ET
$LCI
Biotechnology: Pharmaceutical Preparations
Health Care

NYSE To Suspend Trading Immediately In Lannett Co And Commence Delisting Proceedings

Chat with this insight

Recent Analyst Ratings for $LCI

$LCI Press Releases

Fastest customizable press release news feed in the world

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

LANNETT SHARES UPDATE

LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

$LCI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$LCI Large Ownership Changes

This live feed shows all institutional transactions in real time.

$LCI SEC Filings

$LCI Financials

Live finance-specific insights

$LCI Market Insights

Live Market Insights

SEC Form 4: Chapman John C bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 13% to 174,324 units

SEC Form 4: Lepore Patrick G bought $49,000 worth of shares (100,000 units at $0.49), increasing direct ownership by 21% to 587,145 units

SEC Form 4: Crew Timothy C bought $7,200 worth of shares (15,000 units at $0.48), increasing direct ownership by 3% to 604,291 units

SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

SEC Form EFFECT filed by Lannett Co Inc

SEC Form EFFECT filed by Lannett Co Inc

SEC Form EFFECT filed by Lannett Co Inc

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

Why This Lucid Analyst Is Bullish On The EV Maker Despite Q3 Disappointment

Tesla Soars 10% Amid Musk's China Visit, Lucid Slumps On Stock Sale, Ford-Uber's Win-Win Partnership And More: Biggest EV Stories Of The Week